CVS to Pay $118M to Settle Medicare Advantage Fraud Allegations

Why It Matters

The settlement underscores the financial risk insurers face when risk‑adjustment data is misreported and signals tighter regulatory oversight that could reshape Medicare Advantage profitability.

Key Takeaways

• Aetna settles for $117.7M over Medicare Advantage fraud.
• Allegations involve upcoding diagnoses to inflate risk-adjustment payments.
• DOJ claims coders added unsupported conditions without withdrawing them.
• Settlement avoids litigation but admits no liability.
• Administration may tighten risk-adjustment rules to curb upcoding.

Pulse Analysis

Medicare Advantage’s risk‑adjustment model was designed to reward insurers for caring for sicker beneficiaries, but it also creates a lucrative incentive to overstate health conditions. By assigning higher risk scores, plans receive larger per‑member payments from CMS, encouraging the practice known as upcoding. Industry analysts estimate that such overpayments run into tens of billions annually, prompting federal watchdogs to intensify audits and legal actions against insurers that manipulate diagnosis data.

Aetna’s $117.7 million settlement marks one of the most high‑profile resolutions of these allegations. The DOJ’s complaint detailed a 2015 chart‑review program that paid coders to locate additional diagnoses, some of which lacked supporting medical evidence, and then failed to retract the inflated codes. While CVS Health emphasized that the payment does not constitute an admission of liability, the financial hit and public scrutiny serve as a warning to other Medicare Advantage carriers. Competitors such as UnitedHealthcare and Elevance have already faced similar probes, indicating that the issue spans both large and niche players in the market.

Looking ahead, the current administration is poised to tighten risk‑adjustment safeguards, potentially excluding diagnoses not directly tied to documented care. Such policy shifts could diminish the profitability of aggressive coding strategies and compel insurers to invest in more robust compliance frameworks. For investors and industry observers, the Aetna case highlights the growing importance of governance, data integrity, and regulatory risk management in the evolving landscape of Medicare Advantage.